What is SLXN's current stock price?

SLXN (Silexion Therapeutics Ltd.) is currently trading at $0.50 with a market cap of $280.5K.

What sector is Silexion Therapeutics Ltd. in?

Silexion Therapeutics Ltd. (SLXN) operates in the Healthcare sector, specifically in the Biotechnology industry.

InvestLog

SLXN Silexion Therapeutics Ltd.

Healthcare

$0.50+5.26%ClosedMarket Cap: $280,482

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

5.55

P/S

0.00

EV/EBITDA

0.13

DCF Value

$3.59

FCF Yield

-4283.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-516.9%

ROA

-280.5%

ROIC

1448.8%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-2.7M	$—
Q4 null	$0.00	$-4.4M	$—
FY null	$0.00	$-11.9M	$—
Q3 null	$0.00	$-3.3M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

1 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All

Shirvan Mitchellofficer: CSO and CDO

SellMon Mar 30

Noy Shlomodirector

SellWed Feb 25

Noy Shlomodirector

SellWed Feb 25

Shirvan Mitchellofficer: CSO and CDO

SellMon Feb 23

Peled Amnondirector

SellMon Feb 23

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

-0.29

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Peers